DEA’s mission is to keep American communities safe and healthy and we are in the midst of an overdose crisis that has reached a devastating new height. 265 people die every day from drug overdoses. Countless more [people] overdose and are fortunate to survive. This is a national crisis. It...

Illicit stimulants, specifically cocaine and methamphetamine, remain a pervasive drug threat in Pennsylvania. PFD offices, state/local law enforcement agencies, and other stakeholders throughout Pennsylvania report persistent increases since 2017 in various indicators that demonstrate availability, such as the total quantity of illicit stimulants seized by law enforcement, identification of seized...

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

Due to the efforts of DEA and our partners, from January 2017 through August 2020, we have seen the number of opioid prescriptions drop nearly 37 percent, a reduction in over 47 percent of opioids dispensed, and most importantly -- an 18 percent drop in prescription overdose deaths over the...

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The Drug Enforcement Administration’s (DEA) Philadelphia Field Division (PFD) Intelligence Program conducted an analysis of drug availability and abuse for the State of Delaware. This product highlights significant findings regarding various drug trends since last reported in 2017. The primary drug threats identified in Delaware are illicit opioids, cocaine, controlled...

DEA Acting Administrator Uttam Dhillon announces Operation Crystal Shield in response to a dramatic increase in methamphetamine trafficking through eight major cities in the U.S. The press conference took place at the DEA Field Division Headquarters in Atlanta, Georgia on February 20, 2020.

Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Judiciary Committee for hearing entitled: The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order.